Skip to main content

Peer Review reports

From: Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma

Original Submission
18 Jan 2024 Submitted Original manuscript
23 Mar 2024 Reviewed Reviewer Report
8 May 2024 Reviewed Reviewer Report
19 Jun 2024 Author responded Author comments - Miaoyan Wei
Resubmission - Version 2
19 Jun 2024 Submitted Manuscript version 2
25 Jun 2024 Reviewed Reviewer Report
10 Jul 2024 Reviewed Reviewer Report
19 Aug 2024 Author responded Author comments - Miaoyan Wei
Resubmission - Version 3
19 Aug 2024 Submitted Manuscript version 3
Publishing
22 Aug 2024 Editorially accepted
4 Sep 2024 Article published 10.1186/s12916-024-03581-y

You can find further information about peer review here.

Back to article page